Matrix metalloproteinases and their inhibitors in tumour growth and invasion

Annals of Medicine

Volumn 31, Issue 1, 1999, Pages 34-45

  Kähäri, Veli Matti ^a,c   Saarialho Kere, Ulpu ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer; Invasion; Matrix metalloproteinase

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

CANCER INVASION; EXTRACELLULAR MATRIX; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0033014166     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899909019260     Document Type: Review

References (129)

1. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
2. Kähäri V-M, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997; 6: 199-213.
3. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998; 10: 602-8.
4. Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP, et al. Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem 1996; 271: 28509-15.
5. Freije JMP, Díez-Itza I, Balbín M, Sanchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-73.
6. Knäuper V, López-Otín C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544-50.
7. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner RJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 761-8.
8. Knäuper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997; 272: 7608-16.
9. Fosang AJ, Last K, Knäuper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996; 380: 17-20.
10. Johansson N, Saarialho-Kere U, Airola K, Herva R, Nissinen L, Westermarck J, et al. Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev Dyn 1997; 208: 387-97.
11. Ståhle-Bäckdahl M, Sandstedt B, Bruce K, Lindahl A, Jimeney MG, Vega JA, et al. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab Invest 1997; 76: 717-28.
12. Lindy O, Konttinen, YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997; 40: 1391-9.
13. Vaalamo M, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kähäri VM, et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109: 96-101.
14. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 152: 1005-14.
15. Uitto VJ, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, et al. Collagenase-3 (matrix metalloproteinase-3) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol 1998; 152: 1489-99.
16. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-82.
17. Uría A, Ståhle-Bäckdahl M, Seiki M, Fueyo A, López-Otín C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997; 57: 4882-8.
18. Johansson N, Airola K, Grénman R, Kariniemi A-L, Saarialho-Kere U, Kähäri V-M. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499-508.
19. Airola K, Johansson N, Kariniemi A-L, Kähäri V-M, Saarialho-Kere U. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997; 109: 225-31.
20. Johansson N, Vaalamo M, Grénman S, Hietanen S, Klemi P, Saarialho-Kere U, et al. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999; 154: 469-80.
21. Uría JA, Balbin M, Lopez JM, Alvarez J, Vizoso F, Takigawa M, et al. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998; 153: 91-101.
22. Ståhle-Bäckdahl M, Parks WC. 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol 1993; 142: 995-1000.
23. Aimes RT, Quigley JP. Matrix metalloproteinase is an interstitial collagenase. J Biol Chem 1995; 270: 5872-6.
24. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, et al. Localization of matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase =gelatinase B) in osteoclasts; implications for bone resorption. Lab Invest 1995, 72: 311-22.
25. Vaalamo M, Kariniemi A-L, Shapiro SD, Saarialho-Kere U. Enhanced expression of human metalloelastase (MMP-12) in cutaneous granulomas and macrophage migration. J Invest Dermatol (in press).
26. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61-5.
27. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998; 273: 1216-22.
28. Knäuper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. J Biol Chem 1996; 271: 17124-31.
29. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446-51.
30. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, et al. Membrane type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-7.
31. Matsumoto S, Katoh M, Saito S, Watanabe T, Masuho Y. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Acta 1997; 1354: 159-70.
32. Shofuda KI, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J Biol Chem 1997; 272: 9749-54.
33. Pendas AM, Knäuper V, Puente XS, Llano E, Mattei MG, Aple S, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal localization and tissue distribution. J Biol Chem 1997; 272: 4281-6.
34. Cossins J, Dudgeon TJ, Catlin G, Gearing AJ, Clements JM. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem Biophys Res Commun 1996; 228: 494-8.
35. Llano E, Pendas AM, Knäuper V, Sorsa T, Salo T, Salido E, et al. Identification and characterization of human enamelysin (MMP-20). Biochemistry 1997; 36: 15101-8.
36. Saarialho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995; 105: 190-6.
37. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, et al. Matrilysin expression and function in airway epithelium. J Clin Invest 1998; 102: 1321-31.
38. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, CA: Academic Press; 1998: 300-56.
39. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240-6.
40. Robinson, MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180-6.
41. Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991; 10: 1127-34.
42. Westermarck J, Seth A, Kähäri V-M. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997; 14: 2651-60.
43. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase-1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996; 271: 10672-80.
44. Wernert N, Raes MB, Lassalle P, Dehouck MP, Gosselin B, Vandenbunder B, et al. c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 1992; 140: 119-27.
45. Bolon I, Gouyer V, Devouassoux M, Vandenbunder B, Wernert N, Moro D, et al. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995; 147: 1298-310.
46. Wernert N, Gilles F, Fafeur V, Bouali F, Raes MB, Pyke C, et al. Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 1994; 54: 5683-8.
47. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
48. van Wart H, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87: 5578-82.
49. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997; 15: 511-8.
50. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes TL, Stetler-Stevcnson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin α v β3. Cell 1996; 85: 683-93.
51. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-22.
52. Leco KJ, Khokha R, Pavloff N, Hawkes S, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269: 9352-60.
53. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39-44.
54. Liu YE, Wang M, Greene J, Su J, Ullrich S, Li H, et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997; 272: 20479-83.
55. Airola K, Ahonen M, Johansson N, Kähäri V-M, Saarialho-Kere UK. Human TIMP-3 is expressed during fetal development, hair growth cycle and cancer progression. J Histochem Cytochem 1998; 46: 437-47.
56. Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416-21.
57. Wick M, Burger C, Brusselbach S, Lucibello FC, Muller R. A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation, and senescence. J Biol Chem 1994; 269: 18953-60.
58. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375-80.
59. Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K, Hayakiana T. Induction of angiogenesis in chick yolk sac membrane by polyamines and its inhibition by TIMP and TIMP 2. Biochem Biophys Res Commun 1990; 171: 1264-71.
60. Martin DC, Ruther U, Sanchez-Sweatman OH, Orr FW, Khokha R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 1996; 13: 569-76.
61. Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinases-3. Invest Opthamol Vis Sci 1997; 38: 817-23.
62. Yoshiji H, Buck TB, Harris SR, Ritter LM, Lindsay CK, Thorgeirsson UP. Stimulatory effect of endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpression on type IV collagen and laminin gene expression in rat mammary carcinomas cells. Biochem Biophys Res Commun 1998; 247: 605-9.
63. Yoshiji H, Harris SR, Raso E, Gomey DE, Lindsay CK, Shibuya M, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998; 75: 81-7.
64. Johnsen M, Lund LR, Romer J, Almholt K, Danø K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998; 10: 667-71.
65. Ferrier CM, van Muijen GNP, Ruiter DJ. Proteases in cutaneous melanoma. Ann Med 1998; 30: 431-42.
66. Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997; 15: 535-41.
67. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-2.
68. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998; 185: 256-61.
69. Shima I, Sasapuri Y, Kusukawa J, Fujita H, Kakegava T, Morimatsu M. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathological study. Cancer 1992; 70: 2747-53.
70. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, et al. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993; 53: 165-9.
71. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 Kd type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-9.
72. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi A-L, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer (in press).
73. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 1359-66.
74. Lamport K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998; 153: 429-37.
75. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997; 94: 1402-7.
76. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-51.
77. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998; 140: 1535-41.
78. Kauppila S, Saarela J, Stenbäck F, Risteli J, Kauppila A, Risteli L. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadeno-carcinomas. Am J Pathol 1996; 148: 539-48.
79. Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res 1993; 53: 5028-32.
80. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-9.
81. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997; 272: 24-7.
82. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/ type IV collagenase (MMP-9). J Biol Chem 1997; 272: 28823-5.
83. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998; 37: 4699-702.
84. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88: 801-10.
85. Johansson N, Westermarck J, Leppä S, Häkkinen L, Koivisto L, Lopez-Otin C, et al. Collagenase-3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor-α and transforming growth factor-β. Cell Growth Differ 1997, 8: 243-50.
86. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinase-1. J Natl Cancer Inst 1994; 86: 299-304.
87. Imren S, Kohn DB, Shimada H, Blavier L, DeClerk YA. Overexpression of tissue inhibitor of metalloproteinase-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891-5.
88. Ahonen M, Baker AH, Kähäri V-M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58: 2310-5.
89. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997; 14: 2767-74.
90. Kruger A, Fata JE, Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood 1997; 90: 1993-2000.
91. Chambers AF and Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70.
92. Charous SJ, Stricklin GP, Nanney LB, Netterville JL, Burkey BB. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 1997; 106: 271-8.
93. Polette M, Clavel M, Muller D, Abecassis J, Binninger I, Birembaut P. Detection of mRNAs encoding collagenase 1 and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 1991; 11: 76-83.
94. Polette M, Clavel C, Birembaut P. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 1993; 189: 1052-105.
95. Ring P, Johansson K, Höyhtyä M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. Br J Cancer 1997; 76: 805-11.
96. Wagner SN, Ockenfels HM, Wagner C, Soyer HP, Goos M. Differential expression of tissue inhibitor of metalloproteinases-2 by cutaneous squamous and basal cell carcinomas. J Invest Dermatol 1996; 106: 321-6.
97. Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2, and -3) in oral premalignant lesions, oral squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998; 77: 2239-45.
98. Nuovo GJ, MacDonnell PB, Simsir A, Valea F, French DL. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267-75.
99. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima N. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998; 77: 650-5.
100. Zeng Z, Cohen AM, Zhang Z, Stetler-Stevenson WG, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995; 1: 899-906.
101. Fong KW, Kida Y, Zimmermann PV, Smith PJ. TlMP-1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996; 2: 1369-72.
102. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, et al. High levels of tissue inhibitor of metalloproteinases-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654-9.
103. Powe DG, Brough JL, Carter GI, Ravery V, Angulo J, Shamsa F, et al. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 1997; 75: 1678-83.
104. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994; 10: 199-206.
105. Yoshiji H, Gomez DE, Thorgeirsson UP. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer 1996; 69: 131-4.
106. Karameris A, Panagou P, Tsilalis T, Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. Am J Respir Crit Care Med 1997; 156: 1930-6.
107. Brown PD. Synthetic inhibitors of matrix metalloproteinases. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, CA: Academic Press; 1998; 243-62.
108. Simon C, Juarez J, Nicolson GL, Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. Cancer Res 1996; 56: 5369-74.
109. Reunanen N, Westermarck J, Häkkinen L, Holmström TH, Elo I, Eriksson JE, et al. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998; 273: 5137-45.
110. Ravanti L, Heino J, López-Otín C, Kähäri V-M. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1999; 274: 2446-55.
111. Westermarck J, Holmström TH, Ahonen M, Eriksson JE, Kähäri V-M. Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by Jun N-terminal kinase and p38 stress-activated protein kinase. Matrix Biol 1998; 17: 547-57.
112. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998; 58: 1135-9.
113. Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, et al. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog 1997; 19: 204-12.
114. Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogens 1997; 15: 2069-75.
115. Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ichikawa I, et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998; 76: 812-6.
116. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996; 56: 5279-84.
117. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases-3 (TIMP)-3. Carcinogenesis 1996; 17: 1805-11.
118. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer (in press).
119. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on Batimastat and Marimastat. Pharmacol Ther 1997; 75: 69-75.
120. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic indications for a new family of drugs. Crit Rev Oral Biol Med 1991; 2: 297-322.
121. Uitto VJ, Firth JD, Nip L, Golub LM. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 1994; 732: 140-51.
122. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-α and doxycycline. J Biol Chem 1997; 272: 31504-9.
123. Jonat C, Chung FZ, Baragi VM. Transcriptional down-regulation of stromelysin by tetracycline. J Cell Biochem 1996; 60: 341-7.
124. Fife RS, Rougraff BT, Proctor C, Sledge GW Jr. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997; 130: 530-4.
125. Fife RS, Sledge GW Jr, Roth BJ, Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett 1998; 127: 37-41.
126. Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, et al. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res 1997; 76: 1529-37.
127. Blomqvist C, Elomaa I. Bisphosphonate therapy in metastatic breast cancer. Acta Oncol 1996; Suppl 5: 81-3.
128. Stearns ME. Alendronate blocks TGF-β1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis 1998; 16: 332-9.
129. Farina AR, Tacconeli A, Teti A, Gulino A, Mackay AR. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. Cancer Res 1998; 58: 2957-60.